| A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379 (NCT07712718) | Mirum Pharmaceuticals, Inc. | 2026-05-29 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide (NCT07454837) | Mirum Pharmaceuticals, Inc. | 2026-02-26 |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) (NCT07298330) | Mirum Pharmaceuticals, Inc. | 2026-01-14 |
| Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (NCT07209462) | Mirum Pharmaceuticals, Inc. | 2025-11-22 |
| Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) (NCT07290257) | Mirum Pharmaceuticals, Inc. | 2025-09-25 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) (NCT07200908) | Mirum Pharmaceuticals, Inc. | 2025-08-27 |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (NCT06907290) | Mirum Pharmaceuticals, Inc. | 2025-03-25 |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) (NCT06193928) | Mirum Pharmaceuticals, Inc. | 2023-09-21 |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (NCT05050136) | Mirum Pharmaceuticals, Inc. | 2021-09-22 |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (NCT04729751) | Mirum Pharmaceuticals, Inc. | 2021-09-09 |
| Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (NCT04524390) | Mirum Pharmaceuticals, Inc. | 2021-07-08 |
| A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) (NCT04718961) | Mirum Pharmaceuticals, Inc. | 2021-01-04 |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (NCT04663308) | Mirum Pharmaceuticals, Inc. | 2020-12-18 |
| Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE) (NCT04270682) | Mirum Pharmaceuticals, Inc. | 2020-01-31 |
| MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (NCT04168385) | Mirum Pharmaceuticals, Inc. | 2020-01-16 |
| An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) (NCT04185363) | Mirum Pharmaceuticals, Inc. | 2020-01-08 |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (NCT03905330) | Mirum Pharmaceuticals, Inc. | 2019-07-09 |
| A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) (NCT03353454) | Mirum Pharmaceuticals, Inc. | 2018-10-25 |